1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Swiss R&D Innovation: A Tale Of Two Firms Developing Cell Therapies For Wounds

Dermatology Takes The Spotlight

 
• By Ayisha Sharma

While perhaps best known for historical achievements in immuno-oncology and CNS disorders, the Swiss biotech sector is slowly cultivating a new area of expertise in dermatology. Scrip spoke with two firms applying cell therapy technologies to the challenging area of chronic and acute wounds.  

Swiss Biotech Focus
• Source: Shutterstock

The Swiss biotech sector often reflects global trends, with many firms active in developing cancer therapeutics. The nation has a particularly strong track record in antibody R&D and was ranked as a key growth center for oncology by McKinsey & Company in 2021, defined as countries with the largest growth in company numbers in the relevant therapeutic area since 2015.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

 
• By Joseph Haas

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

J&J Dreams Of ICONIC Status For Icotrokinra

 
• By Kevin Grogan

Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.

Novartis Joins MRGPRX2 Race Through $800m+ Kyorin Deal

 
• By Lisa Takagi

Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.

More from Therapy Areas

Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success

 
• By Alaric DeArment

The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 
• By Andrew McConaghie

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By Kevin Grogan

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.